Dr. Christopher J. Richards, M.D.
Pulmonology (Pulmonary Disease Physician)
- Medicare participating
At a glance
- Medical school
- Harvard Medical School (2011)
- Years since graduation
- 15
- In the NPI registry since
- 2011
- Medicare patients seen, 2024
- 532
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2011Medical school: Harvard Medical School
- 2011Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pulmonary Disease Physician primary
MA license 258089
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Brigham and Women's Hospital Boston, MA
- Massachusetts General Hospital Boston, MA
- Newton-Wellesley Hospital Newton, MA
- North Shore Medical Center - Salem, MA
- Massachusetts Eye and Ear Infirmary - Boston, MA
Medical groups
- Massachusetts General Physicians Organization Inc (3,558 clinicians)
- The General Hospital Corporation (1,267 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 532
- Services billed
- 1,036
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 322 | 225 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 213 | 44 |
| Test to measure rate of airflow | 176 | 172 |
| Test to examine how well the lungs exchange gases | 159 | 159 |
| Critical care, first 30-74 minutes | 102 | 46 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 63 | 63 |
| Established patient office or other outpatient visit, 30-39 minutes | 56 | 51 |
| Test to determine lung volumes using gas dilution or washout | 51 | 51 |
| Telephone medical discussion with physician, 21-30 minutes | 42 | 35 |
| Test to determine lung volumes using sensors | 40 | 40 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Trelegy Ellipta (fluticasone/umeclidin/vilanter) Other prescribers in Boston, MA | 135 |
| Albuterol Sulfate Hfa (albuterol sulfate) Other prescribers in Boston, MA | 57 |
| Anoro Ellipta (umeclidinium brm/vilanterol tr) Other prescribers in Boston, MA | 49 |
| Montelukast Sodium Other prescribers in Boston, MA | 39 |
| Azithromycin Other prescribers in Boston, MA | 31 |
| Dupixent Pen (dupilumab) Other prescribers in Boston, MA | 28 |
| Breztri Aerosphere (budesonide/glycopyr/formoterol) Other prescribers in Boston, MA | 22 |
| Trikafta (elexacaftor/tezacaftor/ivacaft) | 21 |
| Prednisone Other prescribers in Boston, MA | 20 |
| Breo Ellipta (fluticasone/vilanterol) Other prescribers in Boston, MA | 20 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 3 companies reported 14 payments worth $18,534 in total to this clinician.
| Insmed, Inc. | $14,641 |
|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | $3,801 |
| Verona Pharma, Inc. | $92.28 |
| Consulting Fee | $16,072 |
|---|---|
| Travel and Lodging | $1,969 |
| Food and Beverage | $493 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Insmed, Inc. Sep 19, 2025 | Consulting Fee | $9,216 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Dec 3, 2025 | Consulting Fee | $3,400 |
| Insmed, Inc. Dec 5, 2025 | Consulting Fee | $2,016 |
| Insmed, Inc. Aug 15, 2025 | Consulting Fee | $1,440 |
| Insmed, Inc. Aug 23, 2025 | Travel and Lodging travel to Fairfield, NJ · in-kind | $745 |
| Insmed, Inc. Aug 22, 2025 | Travel and Lodging travel to Fairfield, NJ · in-kind | $559 |
| Insmed, Inc. Dec 5, 2025 | Travel and Lodging travel to Chicago, IL · in-kind | $383 |
| Insmed, Inc. Aug 23, 2025 | Travel and Lodging travel to Fairfield, NJ · in-kind | $282 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 3 companies. The companies reported $152,033 in research payments for these studies, mostly to the institutions running them.
- Study to Evaluate ALIS (Amikacin Liposome Inhalation Suspension) in Participants With Nontuberculous Mycobacterial Lung Infection Caused by Mycobacterium Avium Complex
Insmed, Inc. · Completed · NCT04677569 - Verona
Verona Pharma, Inc. - A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIR…
Boehringer Ingelheim International GmbH
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.